CAHHIGH SIGNALFINANCIAL10-K

Cardinal Health shows exceptional operational performance with 83% increases in both net income and operating income, but concerning liquidity deterioration as operating cash flow plunged 36% and cash reserves declined $1.2B.

The dramatic divergence between record profitability and severely weakened cash generation represents a significant red flag that demands immediate investor attention. This pattern often indicates earnings quality issues, aggressive accounting practices, or unsustainable working capital dynamics that could threaten the company's financial stability despite strong headline earnings.

Comparing 2025-08-12 vs 2024-08-14View on EDGAR →
FINANCIAL ANALYSIS

Cardinal Health delivered outstanding profitability growth with net income surging 83% to $1.6B and operating income matching that gain at $2.3B, while gross profit grew a more modest 10% to $8.2B. However, the company's liquidity position deteriorated sharply with operating cash flow collapsing 36% to $2.4B and cash reserves falling 24% to $3.9B, even as total assets expanded 18% to $53.1B driven primarily by inventory buildup. The stark contradiction between record earnings and deteriorating cash generation, combined with rising debt levels and persistent negative stockholders' equity, signals potential earnings quality concerns that overshadow the impressive profit growth.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+321.6%
$51.0M$215.0M

Interest expense surged 321.6% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
+83.2%
$852.0M$1.6B

Net income grew 83.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+83%
$1.2B$2.3B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-36.3%
$3.8B$2.4B

Operating cash flow fell 36.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-24.5%
$5.1B$3.9B

Cash decreased 24.5% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
+17.7%
$45.1B$53.1B

Asset base grew 17.7% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
+17.5%
$2.1B$2.5B

Debt rose 17.5% — additional borrowing for investment or operations; monitor coverage ratios.

Stockholders Equity
Balance Sheet
+13.4%
-$3.2B-$2.8B

Equity base grew 13.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
+12.5%
$15.0B$16.8B

Inventory built 12.5% — monitor whether demand supports this build or if write-downs may follow.

Gross Profit
P&L
+10.2%
$7.4B$8.2B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

LANGUAGE CHANGES
NEW — 2025-08-12
PRIOR — 2024-08-14
ADDED
The number of the registrant s common shares, without par value, outstanding as of July 31, 2025, was the following: 238,793,647 .
References to fiscal 2026, 2025, 2024, 2023, 2022, and 2021 are to the fiscal years ended June 30, 2026, 2025, 2024, 2023, 2022, and 2021, respectively.
Fiscal 2023 items and discussions of year-over-year comparisons between fiscal 2024 and fiscal 2023 that are not included in this Form 10-K can be found in Management s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "Fiscal 2024 Form 10-K").
We provide pharmaceuticals and medical products and cost-effective services and solutions that enhance the healthcare system and supply chain efficiency.
We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
+7 more — sign up free →
REMOVED
The number of the registrant s common shares, without par value, outstanding as of July 31, 2024, was the following: 243,845,343 .
References to fiscal 2025, 2024, 2023, 2022, 2021 and 2020 are to the fiscal years ended June 30, 2025, 2024, 2023, 2022, 2021 and 2020, respectively.
This Form 10-K also includes fiscal 2022 items and discussions of year-over-year comparisons between fiscal 2023 and fiscal 2022.
The periods discussed in this Form 10-K have been revised herein to correct an error identified during the preparation of this Form 10-K, as well as to correct other unrelated immaterial errors.
The revisions ensure comparability across all periods reflected herein.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →